Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.472 USD | +2.14% | -14.77% | -24.29% |
04-24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
04-08 | Gain Therapeutics Names Gene Mack as CFO | MT |
- Stock Market
- Equities
- GANX Stock
- News Gain Therapeutics, Inc.